News

Article

Eyenovia announces commercial availability of clobetasol propionate ophthalmic suspension 0.05% in US

Clobetasol is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery.

(Image Credit: AdobeStock/Drazen)

(Image Credit: AdobeStock/Drazen)

Eyenovia has launched clobetasol propionate ophthalmic suspension 0.05% (Clobetasol) for the treatment of post-operative inflammation and pain following ocular surgery in the United States.

Clobetasol was approved by the US Food and Drug Administration (FDA) in March of 2024. Prior to the FDA approval, Eyenovia had acquired the commercial rights to Clobetasol from Formosa in August 2023. Formosa will be eligible for payments related to Eyenovia's attainment of sales milestones.

Michael Rowe, CEO of Eyenovia, commented on the commercial launch in a press release from the company stating,1 “The commercial launch of Clobetasol represents a significant milestone for our company, and as the first new ophthalmic steroid to be approved in more than 15 years, a meaningful advancement in the field of ocular surgery. With its efficacy and safety profile, convenient twice-a-day dosing regimen, and streamlined distribution that is designed to eliminate complications from insurance, we believe Clobetasol will generate strong interest among eye doctors.”

Clobetasol is a potent steroid derived from Formosa Pharma's proprietary Active Pharmaceutical Nanoparticle Technology (APNT) formulation platform. Its twice-daily dosing regimen is a step away from most other post-surgical eye drops.

Eyenovia also conducted a survey in 100 ophthalmic surgeons to view their opinions on Clobetasol. According to the company,1 results showed that efficacy was the most important characteristic of a post-operative steroid, and based solely on a review of the approved label and the way it will be distributed, majority of respondents indicated a high level of interest in prescribing Clobetasol.

Those surveyed also noted that the safety information of Clobetasol as well as the “low fixed price” were positives of the drop and something that would help them to consider prescribing the drug to patients.

References:
  1. Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery. Press Release; September 26, 2024. Accessed September 30, 2024. https://ir.eyenovia.com/news-releases/news-release-details/eyenovia-announces-launch-and-commercial-availability-clobetasol

Related Videos
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.